US Stock MarketDetailed Quotes

SCNI Scinai Immunotherapeutics

Watchlist
  • 3.750
  • -0.390-9.42%
Close May 28 16:00 ET
  • 3.820
  • +0.070+1.87%
Post 19:48 ET
2.18MMarket Cap-234P/E (TTM)

Scinai Immunotherapeutics Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
(Q2)Jun 30, 2022
(Q1)Mar 31, 2022
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
-12.25%9.71M
-39.68%1.82M
-2.73%2.1M
-20.47%2.6M
21.84%3.19M
1.83%11.06M
-12.26%3.02M
-15.40%2.16M
19.34%3.26M
29.27%2.62M
Selling and administrative expenses
-14.94%4.51M
-24.12%1.21M
0.10%968K
-11.48%1.14M
-17.98%1.19M
-30.54%5.3M
-30.38%1.59M
-49.79%967K
-40.06%1.29M
21.06%1.45M
Research and development costs
-9.63%5.21M
-56.28%627K
-5.03%1.13M
-26.34%1.45M
71.54%2M
77.44%5.77M
22.00%1.43M
89.96%1.19M
238.26%1.97M
41.22%1.16M
Other operating expenses
---9K
----
----
----
----
----
----
----
----
----
Operating profit
12.25%-9.71M
39.68%-1.82M
2.73%-2.1M
20.47%-2.6M
-21.84%-3.19M
-1.83%-11.06M
12.26%-3.02M
15.40%-2.16M
-19.34%-3.26M
-29.27%-2.62M
Net non-operating interest income expense
-96.20%115K
16.89%-3.6M
-24.93%5.21M
-516.79%-1.17M
-335.00%-329K
-3.60%3.03M
-190.16%-4.33M
2,821.55%6.94M
129.49%280K
132.67%140K
Non-operating interest income
-95.97%123K
----
----
----
----
-3.20%3.05M
----
----
----
----
Total other finance cost
-61.90%8K
-49.58%3.72M
24.93%-5.21M
516.79%1.17M
335.00%329K
133.33%21K
--7.38M
---6.94M
---280K
---140K
Other net income (expense)
38.30%3.09M
558.93%2.24M
Gain on sale of security
38.30%3.09M
----
----
----
----
558.93%2.24M
----
----
----
----
Income before tax
-12.15%-6.5M
54.46%-2.33M
-34.97%3.11M
-26.11%-3.76M
-42.02%-3.52M
29.37%-5.8M
-688.08%-5.12M
270.08%4.78M
19.02%-2.98M
-0.96%-2.48M
Income tax
Net income
-12.15%-6.5M
54.46%-2.33M
-34.97%3.11M
-26.11%-3.76M
-42.02%-3.52M
29.37%-5.8M
-688.08%-5.12M
270.08%4.78M
19.02%-2.98M
-0.96%-2.48M
Net income continuous Operations
-12.15%-6.5M
54.46%-2.33M
-34.97%3.11M
-26.11%-3.76M
-42.02%-3.52M
29.37%-5.8M
-688.08%-5.12M
270.08%4.78M
19.02%-2.98M
-0.96%-2.48M
Minority interest income
Net income attributable to the parent company
-12.15%-6.5M
54.46%-2.33M
-34.97%3.11M
-26.11%-3.76M
-42.02%-3.52M
29.37%-5.8M
-688.08%-5.12M
270.08%4.78M
19.02%-2.98M
-0.96%-2.48M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-12.15%-6.5M
54.46%-2.33M
-34.97%3.11M
-26.11%-3.76M
-42.02%-3.52M
29.37%-5.8M
-688.08%-5.12M
270.08%4.78M
19.02%-2.98M
-0.96%-2.48M
Basic earnings per share
60.00%-16
77.78%-8
-80.00%8
25.00%-12
0.00%-12
50.00%-40
-101.24%-36
261.00%40
56.59%-16
49.91%-12
Diluted earnings per share
60.00%-16
77.78%-8
-80.00%8
25.00%-12
0.00%-12
50.00%-40
-101.24%-36
261.00%40
56.59%-16
49.91%-12
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022(Q2)Jun 30, 2022(Q1)Mar 31, 2022
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense -12.25%9.71M-39.68%1.82M-2.73%2.1M-20.47%2.6M21.84%3.19M1.83%11.06M-12.26%3.02M-15.40%2.16M19.34%3.26M29.27%2.62M
Selling and administrative expenses -14.94%4.51M-24.12%1.21M0.10%968K-11.48%1.14M-17.98%1.19M-30.54%5.3M-30.38%1.59M-49.79%967K-40.06%1.29M21.06%1.45M
Research and development costs -9.63%5.21M-56.28%627K-5.03%1.13M-26.34%1.45M71.54%2M77.44%5.77M22.00%1.43M89.96%1.19M238.26%1.97M41.22%1.16M
Other operating expenses ---9K------------------------------------
Operating profit 12.25%-9.71M39.68%-1.82M2.73%-2.1M20.47%-2.6M-21.84%-3.19M-1.83%-11.06M12.26%-3.02M15.40%-2.16M-19.34%-3.26M-29.27%-2.62M
Net non-operating interest income expense -96.20%115K16.89%-3.6M-24.93%5.21M-516.79%-1.17M-335.00%-329K-3.60%3.03M-190.16%-4.33M2,821.55%6.94M129.49%280K132.67%140K
Non-operating interest income -95.97%123K-----------------3.20%3.05M----------------
Total other finance cost -61.90%8K-49.58%3.72M24.93%-5.21M516.79%1.17M335.00%329K133.33%21K--7.38M---6.94M---280K---140K
Other net income (expense) 38.30%3.09M558.93%2.24M
Gain on sale of security 38.30%3.09M----------------558.93%2.24M----------------
Income before tax -12.15%-6.5M54.46%-2.33M-34.97%3.11M-26.11%-3.76M-42.02%-3.52M29.37%-5.8M-688.08%-5.12M270.08%4.78M19.02%-2.98M-0.96%-2.48M
Income tax
Net income -12.15%-6.5M54.46%-2.33M-34.97%3.11M-26.11%-3.76M-42.02%-3.52M29.37%-5.8M-688.08%-5.12M270.08%4.78M19.02%-2.98M-0.96%-2.48M
Net income continuous Operations -12.15%-6.5M54.46%-2.33M-34.97%3.11M-26.11%-3.76M-42.02%-3.52M29.37%-5.8M-688.08%-5.12M270.08%4.78M19.02%-2.98M-0.96%-2.48M
Minority interest income
Net income attributable to the parent company -12.15%-6.5M54.46%-2.33M-34.97%3.11M-26.11%-3.76M-42.02%-3.52M29.37%-5.8M-688.08%-5.12M270.08%4.78M19.02%-2.98M-0.96%-2.48M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -12.15%-6.5M54.46%-2.33M-34.97%3.11M-26.11%-3.76M-42.02%-3.52M29.37%-5.8M-688.08%-5.12M270.08%4.78M19.02%-2.98M-0.96%-2.48M
Basic earnings per share 60.00%-1677.78%-8-80.00%825.00%-120.00%-1250.00%-40-101.24%-36261.00%4056.59%-1649.91%-12
Diluted earnings per share 60.00%-1677.78%-8-80.00%825.00%-120.00%-1250.00%-40-101.24%-36261.00%4056.59%-1649.91%-12
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion with Explanatory Notes--------Unqualified Opinion--------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg